Gene Logic to Reposition Discontinued Drug Candidates for Merck Serono | GenomeWeb
NEW YORK (GenomeWeb News) — Gene Logic today said it will help Merck Serono, a division of German drug maker Merck, identify alternative development paths for “several” undisclosed drug candidates.
 
All of the candidates were discontinued or “de-prioritized” in clinical trials for reasons other than safety, according to Gene Logic.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.